Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

14%(1 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 2Efficacy & side effects

7(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 27 (100.0%)

Trials by Status

completed7100%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_2

Clinical Trials (7)

Showing 7 of 7 trials

NCT00035113Phase 2

EPO906 Therapy in Patients With Prostate Cancer

Completed

NCT00035126Phase 2

EPO906 Therapy in Patients With Advanced Breast Cancer

Completed

NCT00450866Phase 2

Epothilone B in Treating Patients With CNS Metastases From Breast Cancer

Completed

NCT00035087Phase 2

EPO906 Therapy in Patients With Advanced Colorectal Cancer

Completed

NCT00035165Phase 2

EPO906 Therapy in Patients With Advanced Melanoma

Completed

NCT00035243Phase 2

EPO906 Therapy in Patients With Advanced Kidney Cancer

Completed

NCT00035100Phase 2

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7